E. S. Casper

3.4k total citations · 1 hit paper
32 papers, 2.6k citations indexed

About

E. S. Casper is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, E. S. Casper has authored 32 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in E. S. Casper's work include Cancer Treatment and Pharmacology (7 papers), Sarcoma Diagnosis and Treatment (7 papers) and Lung Cancer Treatments and Mutations (5 papers). E. S. Casper is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Sarcoma Diagnosis and Treatment (7 papers) and Lung Cancer Treatments and Mutations (5 papers). E. S. Casper collaborates with scholars based in United States, New Zealand and Canada. E. S. Casper's co-authors include Murray F. Brennan, Peter W. T. Pisters, James M. Woodruff, L.B. Harrison, Denis H. Y. Leung, Paul A. Meyers, Glenn Heller, John H. Healey, Mace L. Rothenberg and John Sahl Andersen and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Neurology and British Journal of Cancer.

In The Last Decade

E. S. Casper

31 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.

1996 731 citations Peter W. T. Pisters, L.B. Harrison et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. S. Casper United States	17	1.7k	1.6k	533	487	457	32	2.6k
Gunnar Sæter Norway	33	1.3k 0.8×	2.4k 1.6×	507 1.0×	1.0k 2.1×	646 1.4×	77	3.4k
G Westbury United Kingdom	26	1.3k 0.8×	837 0.5×	173 0.3×	372 0.8×	805 1.8×	72	2.4k
Antonio López–Pousa Spain	32	1.7k 1.0×	1.9k 1.2×	448 0.8×	280 0.6×	804 1.8×	161	3.4k
Federica Grosso Italy	33	1.8k 1.0×	3.0k 2.0×	621 1.2×	633 1.3×	535 1.2×	158	4.4k
Frank Willeke Germany	32	1.4k 0.8×	1.1k 0.7×	386 0.7×	254 0.5×	1.1k 2.4×	102	3.0k
Fariba Navid United States	31	896 0.5×	1.3k 0.8×	303 0.6×	362 0.7×	416 0.9×	104	2.8k
Alessandro Comandone Italy	25	1.4k 0.8×	2.3k 1.5×	539 1.0×	913 1.9×	621 1.4×	103	3.0k
C B Pratt United States	29	975 0.6×	842 0.5×	185 0.3×	202 0.4×	384 0.8×	65	2.6k
Henri Porte France	26	684 0.4×	1.5k 0.9×	194 0.4×	199 0.4×	787 1.7×	77	2.8k
J. Buesa Spain	26	2.1k 1.2×	2.9k 1.9×	769 1.4×	333 0.7×	687 1.5×	61	3.6k

Countries citing papers authored by E. S. Casper

Since Specialization

Citations

This map shows the geographic impact of E. S. Casper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. S. Casper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. S. Casper more than expected).

Fields of papers citing papers by E. S. Casper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. S. Casper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. S. Casper. The network helps show where E. S. Casper may publish in the future.

Co-authorship network of co-authors of E. S. Casper

This figure shows the co-authorship network connecting the top 25 collaborators of E. S. Casper. A scholar is included among the top collaborators of E. S. Casper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. S. Casper. E. S. Casper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shah, Manish A., David H. Ilson, Rajesh Ramanathan, et al.. (2005). A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology. 23(16_suppl). 4025–4025. 16 indexed citations

Meyers, Paul A., Richard Görlick, Glenn Heller, et al.. (1998). Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol.. Journal of Clinical Oncology. 16(7). 2452–2458. 233 indexed citations

Rothenberg, Mace L., Malcolm J. Moore, M. Christine Cripps, et al.. (1996). A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Annals of Oncology. 7(4). 347–353. 455 indexed citations

Pisters, Peter W. T., L.B. Harrison, Denis H. Y. Leung, et al.. (1996). Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.. Journal of Clinical Oncology. 14(3). 859–868. 731 indexed citations breakdown →

Brennan, MF, Daphna Pollack, E. S. Casper, et al.. (1995). Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. British Journal of Cancer. 72(4). 986–991. 51 indexed citations

Kushner, Brian H., Paul A. Meyers, William L. Gerald, et al.. (1995). Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.. Journal of Clinical Oncology. 13(11). 2796–2804. 133 indexed citations

Cordon‐Cardo, Carlos, J Sorvillo, E. S. Casper, et al.. (1992). Expression of epidermal growth factor receptor and transforming growth factor alpha in human myogenic sarcomas. Journal of Experimental & Clinical Cancer Research. 11(2). 83–91. 1 indexed citations

Garberoglio, Carlos A., et al.. (1992). Expression of P-glycoprotein in normal muscle cells and myogenic tumors.. PubMed. 116(10). 1055–61. 16 indexed citations

Gaynor, Jeffrey J., E. S. Casper, Charles Collin, et al.. (1992). Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults.. Journal of Clinical Oncology. 10(8). 1317–1329. 210 indexed citations

10.

Crown, John, E. S. Casper, J F Botet, P Murray, & David P. Kelsen. (1991). Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma.. Journal of Clinical Oncology. 9(9). 1682–1686. 100 indexed citations

11.

Jakubowski, Ann A., E. S. Casper, Janice Gabrilove, et al.. (1989). Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer.. Journal of Clinical Oncology. 7(3). 298–303. 62 indexed citations

12.

Chapman, Paul B., E. S. Casper, Janice Gabrilove, et al.. (1987). Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.. Journal of Clinical Oncology. 5(12). 1942–1951. 183 indexed citations

13.

Kris, Mark G., R. Gralla, Leonard Kalman, et al.. (1985). Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Lung Cancer. 1(3-4). 79–79. 70 indexed citations

14.

Casper, E. S., Nancy L. Geller, T. Hakes, et al.. (1985). A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.. Journal of Clinical Oncology. 3(6). 818–826. 195 indexed citations

15.

Mittelman, A, et al.. (1983). Phase I study of tricyclic nucleoside phosphate.. PubMed. 67(2). 159–62. 17 indexed citations

16.

Casper, E. S., R. Gralla, Richard J. Kaufman, & Charles W. Young. (1981). Aclacinomycin-A: Phase I trial in patients with solid tumors. Proceedings of the American Association for Cancer Research. 22.

17.

Itri, Loretta M., Richard J. Gralla, & E. S. Casper. (1981). Vindesine with cisplatin in non-small lung cancer (NSCLC): The influence on survival and the effect of adding conventional agents. Proceedings of the American Association for Cancer Research. 22. 1 indexed citations

18.

Chapman, Robert, D. P. Kelsen, Richard J. Gralla, et al.. (1981). Phase II trial of methylglyoxal-bis-(guanylhydrazone) in non-small-cell lung cancer.. PubMed. 4(4). 389–91. 5 indexed citations

19.

Gralla, R., E. S. Casper, Robert B. Golbey, & Charles W. Young. (1979). Phase I and preliminary phase II studies with N-(phosphonacetyl)-L-aspartic acid (PALA). Proceedings of the American Association for Cancer Research. 20. 3 indexed citations

20.

Casper, E. S., Richard J. Gralla, & Robert B. Golbey. (1979). Vindesine (DVA) and cis-dichlorodiammineplatinum II (DDP) combination chemotherapy in non-small cell lung cancer (NSCLC). Proceedings of the American Association for Cancer Research. 20. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact